Skip Nav Destination
Quantitative FDG-PET: a new biomarker in PMBCL
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232
Recurrent CDKN1B (p27) mutations in hairy cell leukemia
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL
Issue Archive
August 20 2015
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
INSIDE BLOOD COMMENTARY
Quantitative FDG-PET: a new biomarker in PMBCL
Clinical Trials & Observations
PLENARY PAPER
PLENARY PAPER
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
Clinical Trials & Observations
Luca Ceriani,Maurizio Martelli,Pier Luigi Zinzani,Andrés J. M. Ferreri,Barbara Botto,Caterina Stelitano,Manuel Gotti,Maria Giuseppina Cabras,Luigi Rigacci,Livio Gargantini,Francesco Merli,Graziella Pinotti,Donato Mannina,Stefano Luminari,Anastasios Stathis,Eleonora Russo,Franco Cavalli,Luca Giovanella,Peter W. M. Johnson,Emanuele Zucca
Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival
Clinical Trials & Observations
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232
Clinical Trials & Observations
Michael J. Borowitz,Brent L. Wood,Meenakshi Devidas,Mignon L. Loh,Elizabeth A. Raetz,Wanda L. Salzer,James B. Nachman,Andrew J. Carroll,Nyla A. Heerema,Julie M. Gastier-Foster,Cheryl L. Willman,Yunfeng Dai,Naomi J. Winick,Stephen P. Hunger,William L. Carroll,Eric Larsen
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Recurrent CDKN1B (p27) mutations in hairy cell leukemia
Brief Report
Sascha Dietrich,Jennifer Hüllein,Stanley Chun-Wei Lee,Barbara Hutter,David Gonzalez,Sandrine Jayne,Martin J. S. Dyer,Małgorzata Oleś,Monica Else,Xiyang Liu,Mikołaj Słabicki,Bian Wu,Xavier Troussard,Jan Dürig,Mindaugas Andrulis,Claire Dearden,Christof von Kalle,Martin Granzow,Anna Jauch,Stefan Fröhling,Wolfgang Huber,Manja Meggendorfer,Torsten Haferlach,Anthony D. Ho,Daniela Richter,Benedikt Brors,Hanno Glimm,Estella Matutes,Omar Abdel Wahab,Thorsten Zenz
MYELOID NEOPLASIA
Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
CME
Stéphane Barete,Olivier Lortholary,Gandhi Damaj,Isabelle Hirsch,Marie Olivia Chandesris,Caroline Elie,Mohamed Hamidou,Isabelle Durieu,Felipe Suarez,Bernard Grosbois,Nicolas Limal,Emmanuel Gyan,Claire Larroche,Gérard Guillet,Jean Emmanuel Kahn,Philippe Casassus,Karima Amazzough,Hélène Coignard-Biehler,Sophie Georgin-Lavialle,Ludovic Lhermitte,Sylvie Fraitag,Danielle Canioni,Patrice Dubreuil,Olivier Hermine
PLATELETS AND THROMBOPOIESIS
TRANSPLANTATION
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation
Laurent Pascal,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Luciana Tucunduva,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Annalisa Ruggeri,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Didier Blaise,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Patrice Ceballos,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Patrice Chevallier,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Jan Cornelissen,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Natacha Maillard,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Reza Tabrizi,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Eefke Petersen,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Werner Linkesch,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Henrik Sengeloev,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Chantal Kenzey,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Antonio Pagliuca,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Ernst Holler,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Hermann Einsele,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Eliane Gluckman,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Vanderson Rocha,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation,Ibrahim Yakoub-Agha,on behalf of Eurocord and the European Society for Blood and Marrow Transplantation
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Clinical Trials & Observations
Stefan O. Ciurea,Mei-Jie Zhang,Andrea A. Bacigalupo,Asad Bashey,Frederick R. Appelbaum,Omar S. Aljitawi,Philippe Armand,Joseph H. Antin,Junfang Chen,Steven M. Devine,Daniel H. Fowler,Leo Luznik,Ryotaro Nakamura,Paul V. O’Donnell,Miguel-Angel Perales,Sai Ravi Pingali,David L. Porter,Marcie R. Riches,Olle T. H. Ringdén,Vanderson Rocha,Ravi Vij,Daniel J. Weisdorf,Richard E. Champlin,Mary M. Horowitz,Ephraim J. Fuchs,Mary Eapen
BLOOD WORK
CORRESPONDENCE
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
Clinical Trials & Observations
Panagiotis Baliakas,Anastasia Hadzidimitriou,Andreas Agathangelidis,Davide Rossi,Lesley-Ann Sutton,Jana Kminkova,Lydia Scarfo,Sarka Pospisilova,Gianluca Gaidano,Kostas Stamatopoulos,Paolo Ghia,Richard Rosenquist
The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL
Clinical Trials & Observations
Michaela Kotrova,Katerina Muzikova,Ester Mejstrikova,Michaela Novakova,Violeta Bakardjieva-Mihaylova,Karel Fiser,Jan Stuchly,Mathieu Giraud,Mikaël Salson,Christiane Pott,Monika Brüggemann,Marc Füllgrabe,Jan Stary,Jan Trka,Eva Fronkova
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Normal human bone marrow (BM) mesenchymal stem cells (MSC) are able to differentiate toward cells of different lineages, including adipogenic, osteogenic, and chondrogenic cells. The figure shows the adipocytes that differentiated from normal BM-derived MSCs after incubation for 14 days in medium that favored adipocyte formation. Adipocytes were stained with the fatty acid–binding protein 4 (FABP4) antibody as green, and the nuclei were stained with 4′,6-diamidino-2-phenylindole as blue. See the article by Lu et al on page 972.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
